Practice guideline for the treatment of patients with major depressive disorder, 2010. ,
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the, 2000. ,
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database, Human Psychopharmacology: Clinical and Experimental, vol.159, issue.Suppl, pp.269-75, 2009. ,
DOI : 10.1002/hup.1019
The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data, European Psychiatry, vol.27, issue.7, pp.522-529, 2012. ,
DOI : 10.1016/j.eurpsy.2011.05.002
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder, The World Journal of Biological Psychiatry, vol.34, issue.3, pp.5-43, 2002. ,
DOI : 10.1001/archpsyc.58.1.55
Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression, The British Journal of Psychiatry, vol.176, issue.5, pp.421-429, 2000. ,
DOI : 10.1192/bjp.176.5.421
Social Functioning, CNS Drugs, vol.4, issue.3, pp.313-337, 2005. ,
DOI : 10.2165/00023210-200519040-00004
Statistical Inference for Generalized Yule Coefficients in 2 ?? 2 Contingency Tables, Sociological Methods & Research, vol.75, issue.3, pp.429-475, 2007. ,
DOI : 10.1177/0049124106292358
The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine, Journal of Affective Disorders, vol.31, issue.3, pp.151-64, 1994. ,
DOI : 10.1016/0165-0327(94)90024-8
Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples, Psychological Medicine, vol.120, issue.01, pp.135-144, 1982. ,
DOI : 10.1016/S0140-6736(78)90003-X
How Fast Are Antidepressants?, The Journal of Clinical Psychiatry, vol.61, issue.10, pp.712-733, 2000. ,
DOI : 10.4088/JCP.v61n1002
Toxic Effects of Depression on Brain Function: Impairment of Delayed Recall and the Cumulative Length of Depressive Disorder in a Large Sample of Depressed Outpatients, American Journal of Psychiatry, vol.165, issue.6, pp.731-740, 2008. ,
DOI : 10.1176/appi.ajp.2008.07040574
Review: Restoring circadian rhythms: a new way to successfully manage depression, Journal of Psychopharmacology, vol.24, issue.2 Suppl, pp.15-24, 2010. ,
DOI : 10.1177/1359786810372981
A RATING SCALE FOR DEPRESSION, Journal of Neurology, Neurosurgery & Psychiatry, vol.23, issue.1, pp.56-62, 1960. ,
DOI : 10.1136/jnnp.23.1.56
Does early improvement triggered by antidepressants predict response/remission? ??? Analysis of data from a naturalistic study on a large sample of inpatients with major depression, Journal of Affective Disorders, vol.115, issue.3, pp.439-488, 2009. ,
DOI : 10.1016/j.jad.2008.10.011
Novel melatonin-based therapies: potential advances in the treatment of major depression, The Lancet, vol.378, issue.9791, pp.621-652, 2011. ,
DOI : 10.1016/S0140-6736(11)60095-0
Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination, Biological Psychiatry, vol.51, issue.2, pp.123-156, 2002. ,
DOI : 10.1016/S0006-3223(01)01291-4
A phase model of psychotherapy outcome: Causal mediation of change., Journal of Consulting and Clinical Psychology, vol.61, issue.4, pp.678-85, 1993. ,
DOI : 10.1037/0022-006X.61.4.678
The timing, specificity and clinical prediction of tricyclic drug effects in depression, Psychological Medicine, vol.12, issue.02, pp.297-309, 1987. ,
DOI : 10.1192/bjp.143.6.601
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, European Neuropsychopharmacology, vol.16, issue.2, pp.93-100, 2006. ,
DOI : 10.1016/j.euroneuro.2005.09.002
The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys, Epidemiologia e Psichiatria Sociale, vol.49, issue.01, pp.23-33, 2009. ,
DOI : 10.1192/bjp.188.5.465
Improvement within 2weeks and later treatment outcomes in patients with depressive disorders: The CRESCEND study, Journal of Affective Disorders, vol.129, issue.1-3, pp.183-90, 2011. ,
DOI : 10.1016/j.jad.2010.09.007
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults., Journal of Affective Disorders, vol.117, pp.26-43, 2009. ,
DOI : 10.1016/j.jad.2009.06.041
Relationship between brain electrical activity and cortical perfusion in normal subjects, Psychiatry Research: Neuroimaging, vol.90, issue.2, pp.125-165, 1999. ,
DOI : 10.1016/S0925-4927(99)00006-2
A practical approach to the early identification of antidepressant medication non-responders, Psychological Medicine, vol.36, issue.02, pp.309-325, 2012. ,
DOI : 10.1176/appi.ajp.160.4.734
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int Clin Psychopharmacol, vol.17, pp.239-286, 2002. ,
Switching antidepressants for treatment-resistant major depression, J Clin Psychiatry, vol.62, pp.12-19, 2001. ,
Early non-response to fluoxetine as a predictor of poor 8-week outcome, Am J Psychiatry, vol.152, pp.1500-1503, 1995. ,
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study, Current Medical Research and Opinion, vol.23, issue.2, pp.401-417, 2007. ,
DOI : 10.1185/030079906X167453
The economic cost of brain disorders in Europe, European Journal of Neurology, vol.21, issue.Suppl. 14, pp.155-62, 2012. ,
DOI : 10.1111/j.1468-1331.2011.03590.x
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5- HT2C antagonistic properties, in major depressive disorder, Int J Neuropsychopharmacol, vol.10, pp.661-73, 2007. ,
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD, European Neuropsychopharmacology, vol.19, issue.1, pp.34-40, 2009. ,
DOI : 10.1016/j.euroneuro.2008.08.009
The leeds sleep evaluation questionnaire in psychopharmacological investigations?a review, Psychopharmacology, vol.110, issue.Suppl, pp.173-182, 1980. ,
DOI : 10.1007/BF00434408
Is There a Delay in the Antidepressant Effect? A Meta-Analysis, The Journal of Clinical Psychiatry, vol.66, issue.02, pp.148-58, 2005. ,
DOI : 10.4088/JCP.v66n0201
Use of Pattern Analysis to Identify True Drug Response, Archives of General Psychiatry, vol.44, issue.3, pp.259-64, 1987. ,
DOI : 10.1001/archpsyc.1987.01800150071009
Statistical software for metaanalysis . Version 2. Sunderland: Massachusetts: Sinauer Associates, 2000. ,
External validity of randomised controlled trials: ???To whom do the results of this trial apply????, The Lancet, vol.365, issue.9453, pp.82-93, 2005. ,
DOI : 10.1016/S0140-6736(04)17670-8
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression, Biological Psychiatry, vol.54, issue.5, pp.573-83, 2003. ,
DOI : 10.1016/S0006-3223(02)01866-8
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression, New England Journal of Medicine, vol.354, issue.12, pp.1231-1273, 2006. ,
DOI : 10.1056/NEJMoa052963
The measurement of disability, International Clinical Psychopharmacology, vol.11, issue.Supplement 3, pp.89-95, 1996. ,
DOI : 10.1097/00004850-199606003-00015
Role of melatonin in mood disorders and the antidepressant effects of agomelatine, Expert Opinion on Investigational Drugs, vol.21, issue.1, pp.1503-1525, 2012. ,
DOI : 10.1097/FBP.0b013e3280116e5c
Onset of improvement under fluoxetine and moclobemide, European Psychiatry, vol.13, issue.3, pp.128-161, 1998. ,
DOI : 10.1016/S0924-9338(98)80135-1
Metaanalysis of observational studies in epidemiology: a proposal for reporting ,
Effect of Mental Health Care and Shared Decision Making on Patient Satisfaction in a Community Sample of Patients with Depression, Medical Care Research and Review, vol.64, issue.4, pp.416-446, 2007. ,
DOI : 10.1177/1077558707299479
Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.70, issue.3, pp.344-53, 2009. ,
DOI : 10.4088/JCP.07m03780
Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression, Journal of Affective Disorders, vol.120, issue.1-3, pp.86-93, 2010. ,
DOI : 10.1016/j.jad.2009.04.014
Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder, BMC Psychiatry, vol.44, issue.Suppl. 4, p.16, 2011. ,
DOI : 10.1159/000318162
The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders, Psychological Medicine, vol.172, issue.04, pp.1023-1055, 1993. ,
DOI : 10.1192/bjp.153.6.752
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice, American Journal of Psychiatry, vol.163, issue.1, pp.28-40, 2006. ,
DOI : 10.1176/appi.ajp.163.1.28
Time course of response to antidepressants: Predictive value of early improvement and effect of additional psychotherapy, Journal of Affective Disorders, vol.114, issue.1-3, pp.243-53, 2009. ,
DOI : 10.1016/j.jad.2008.07.023
The onset of effect for escitalopram and its relevance for the clinical management of depression, Current Medical Research and Opinion, vol.22, issue.11, pp.2101-2111, 2006. ,
DOI : 10.1185/030079906X148319
Placebo Response in Studies of Major Depression, JAMA, vol.287, issue.14, pp.1840-1847, 2002. ,
DOI : 10.1001/jama.287.14.1840
What to do? Or what do we owe our residents?, Biol Psychiatry, vol.15, pp.599-611, 1980. ,